Results 31 to 40 of about 25,818 (186)

Complete pathological response and negative postoperative ctDNA were not predictive of discontinuation of adjuvant crizotinib therapy in a patient with locally advanced MET ex14 skipping mutation-positive non-small cell lung cancer: a case report

Frontiers in Oncology, 2023
Neoadjuvant targeted therapy is an alternative treatment for locally advanced non-small cell lung cancer (NSCLC) patients with driver gene mutation. MET ex14 mutation is considered a driver gene, and crizotinib is the first oral tyrosine kinase inhibitor
Jiantao Wang, Jiantao Wang, Jiantao Wang, Wenqing Yao, Weiya Wang, Mingyu Fan, Mingyu Fan, Kaili Huang, Kaili Huang, Zhenkun Liu, Zhenkun Liu, Daxing Zhu, Daxing Zhu   +12 more
doaj   +1 more source

Effective Alu repeat based RT-qPCR normalization in cancer cell perturbation experiments [PDF]

, 2013
Background: Measuring messenger RNA (mRNA) levels using the reverse transcription quantitative polymerase chain reaction (RT-qPCR) is common practice in many laboratories.
Beckers, Anneleen, De Brouwer, Sara, Kumps, Candy, Leonelli, Carina, Mestdagh, Pieter, Mets, Evelien, Pattyn, Filip, Rihani, Ali, Rondou, Pieter, Speleman, Franki, Van der Meulen, Joni, Van Maerken, Tom, Van Peer, Gert, Vandesompele, Jo   +13 more
core   +4 more sources

Crizotinib [PDF]

Reactions Weekly, 2021
  +5 more sources

Determination of Crizotinib in Mouse Tissues by LC-MS/MS and Its Application to a Tissue Distribution Study

International Journal of Analytical Chemistry, 2020
Toxicity induced by crizotinib, a small-molecule tyrosine kinase inhibitor, is a significant clinical issue during treatment. A tissue distribution study is required to explore the organs affected by this molecule.
Fang Zhao, Yuan Wei, Yiming Yan, Han Liu, Sitong Zhou, Bo Ren, Ruijuan Liu   +6 more
doaj   +1 more source

Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1G2032R and ALKG1202R

Journal of Enzyme Inhibition and Medicinal Chemistry, 2023
Clinical treatment by FDA-approved ROS1/ALK inhibitor Crizotinib significantly improved the therapeutic outcomes. However, the emergence of drug resistance, especially driven by acquired mutations, have become an inevitable problem and worsened the ...
Siming Liu, Chuan Huang, Chunhui Huang, Yaqi Huang, Yonghuan Yu, Guowu Wu, Fengqiu Guo, Ying Jiang, Shanhe Wan, Zhengguang Zhu, Yuanxin Tian, Jianghua Zhu, Jiajie Zhang   +12 more
doaj   +1 more source

An end-to-end software solution for the analysis of high-throughput single-cell migration data [PDF]

, 2017
The systematic study of single-cell migration requires the availability of software for assisting data inspection, quality control and analysis. This is especially important for high-throughput experiments, where multiple biological conditions are tested
Ampe, Christophe, Huyck, Lynn, Martens, Lennart, Masuzzo, Paola, Simiczyjew, Aleksandra, Van Troys, Marleen   +5 more
core   +2 more sources

Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer. [PDF]

, 2017
Anaplastic lymphoma kinase (ALK) gene rearrangements have been identified in lung cancer at 3-7% frequency, thus representing an important subset of genetic lesions that drive oncogenesis in this disease. Despite the availability of multiple FDA-approved
Bivona, Trever G, Haderk, Franziska, Wu, Wei   +2 more
core   +3 more sources

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

Cancer Medicine, 2019
Objectives Crizotinib has demonstrated good efficacy in patients with anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC). Continuing crizotinib therapy beyond progressive disease (CBPD) can achieve ongoing survival benefit in ...
Guangjian Yang, Di Ma, Haiyan Xu, Lu Yang, Junling Li, Puyuan Xing, Xuezhi Hao, Yan Wang   +7 more
doaj   +1 more source

Tissue distribution of crizotinib and gemcitabine combination in a patient-derived orthotopic mouse model of pancreatic cancer

ADMET and DMPK, 2016
Pharmacokinetics focuses on the question whether a drug actually reaches its target in therapeutic concentrations or accumulates elsewhere, potentially causing toxicological or unpredictable side effects. We determined tissue distribution of gemcitabine,
Richard J. Honeywell, Amir Avan, Elisa Giovannetti, Godefridus J. Peters   +3 more
doaj   +1 more source

Crizotinib in Sarcomatous Malignancies Harboring ALK Fusion With a Definitive Partner(s): Response and Efficacy

Frontiers in Oncology, 2021
Sarcoma or sarcomatoid malignancies are a set of mesenchymal-origin malignancies with vast heterogeneity in clinical and molecular characteristics. Anaplastic lymphoma kinase (ALK) is a tyrosine kinase oncoprotein expressed by several tumors, including ...
Jinchun Wu, Yongbin Hu, Omar Abdihamid, Gengwen Huang, Sheng Xiao, Bin Li   +5 more
doaj   +1 more source